IMFINZI® (durvalumab) | Immunotherapy for Certain Cancers IMFINZI® (durvalumab) is an immunotherapy approved to treat patients with NSCLC, SCLC, bile duct cancer, unresectable hepatocellular carcinoma, muscle-invasive bladder cancer, and advanced or recurrent endometrial cancer Cholangiocarcinoma or Gallbladder Cancer;
What is IMFINZI® (durvalumab) | Approved Treatment for Stage 3 NSCLC IMFINZI ® (durvalumab) is the first immunotherapy treatment approved for adults living with unresectable Stage 3 non-small cell lung cancer (NSCLC) whose disease has not progressed after chemoradiation therapy (CRT) CRT is a combination of chemotherapy and radiation therapy given together
How IMFINZI® (durvalumab) Works Against NSCLC HOW IMFINZI WORKS TO HELP FIGHT NON-SMALL CELL LUNG CANCER (NSCLC) IMFINZI is not chemotherapy or radiation therapy IMFINZI is an immunotherapy, which means it works with the immune system to find and attack unresectable Stage 3 non-small cell lung cancer (NSCLC)
What Is IMFINZI® (durvalumab)? IMFINZI ® (durvalumab) is a prescription medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC) IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same
What is IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) with . . . IMFINZI and IMJUDO can cause serious side effects (see above): The most common side effects of IMFINZI when used in combination with IMJUDO and platinum-containing chemotherapy in adults with metastatic non-small cell lung cancer (mNSCLC) include nausea, feeling tired or weak, muscle or bone pain, decreased appetite, rash, and diarrhea
What is IMFINZI® (durvalumab) – Treatment for ES-SCLC IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called SCLC IMFINZI may be used alone when your LS-SCLC cannot be removed by surgery and has responded or stabilized after initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy
IMFINZI® (durvalumab) Lung problems: cough, shortness of breath, and chest pain Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; and severe stomach-area (abdomen) pain or tenderness Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach
Frequently Asked Questions | IMFINZI® (durvalumab) IMFINZI ® (durvalumab) is the first and only approved immunotherapy for people with unresectable Stage 3 NSCLC whose disease has not progressed following concurrent platinum-based chemoradiation therapy (CRT) See questions to ask your doctor about IMFINZI
Stage 3 Non-Small Cell Lung Cancer Immunotherapy | IMFINZI® (durvalumab) IMFINZI can cause serious side effects (see above): The most common side effects of IMFINZI when used alone in adults with non-small cell lung cancer (NSCLC) that cannot be removed by surgery include cough, feeling tired, inflammation in the lungs, upper respiratory tract infections, shortness of breath, and rash
IMFINZI® (durvalumab) IMFINZI and IMJUDO are prescription medications that may treat certain cancers IMFINZI is used to treat adults with a type of lung cancer called NSCLC IMFINZI may be used alone when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation